Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more
Profound Medical Corp (PROF) - Net Assets
Latest net assets as of September 2025: $32.14 Million USD
Based on the latest financial reports, Profound Medical Corp (PROF) has net assets worth $32.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.30 Million) and total liabilities ($10.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.14 Million |
| % of Total Assets | 75.98% |
| Annual Growth Rate | 46.04% |
| 5-Year Change | -37.93% |
| 10-Year Change | 500.47% |
| Growth Volatility | 244.35 |
Profound Medical Corp - Net Assets Trend (2014–2024)
This chart illustrates how Profound Medical Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Profound Medical Corp (2014–2024)
The table below shows the annual net assets of Profound Medical Corp from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $60.42 Million | +93.51% |
| 2023-12-31 | $31.22 Million | -39.96% |
| 2022-12-31 | $52.00 Million | -35.41% |
| 2021-12-31 | $80.51 Million | -17.30% |
| 2020-12-31 | $97.35 Million | +581.32% |
| 2019-12-31 | $14.29 Million | -26.91% |
| 2018-12-31 | $19.55 Million | +73.84% |
| 2017-12-31 | $11.25 Million | +1.88% |
| 2016-12-31 | $11.04 Million | +9.70% |
| 2015-12-31 | $10.06 Million | +635.46% |
| 2014-12-31 | $1.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Profound Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24471684975.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $281.55 Million | 465.98% |
| Other Comprehensive Income | $2.74 Million | 4.54% |
| Other Components | $21.30 Million | 35.25% |
| Total Equity | $60.42 Million | 100.00% |
Profound Medical Corp Competitors by Market Cap
The table below lists competitors of Profound Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kowloon Development Company Limited
F:KOX
|
$169.46 Million |
|
Changzhou Evergreen Technology Co. Ltd. A
SHE:001324
|
$169.48 Million |
|
Zhejiang Bofay Elec Co Ltd
SHE:001255
|
$169.49 Million |
|
IFE Elevators Co Ltd
SHE:002774
|
$169.51 Million |
|
Quest Holdings S.A
AT:QUEST
|
$169.40 Million |
|
Okea ASA
OL:OKEA
|
$169.34 Million |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
$169.34 Million |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
$169.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Profound Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,224,000 to 60,422,000, a change of 29,198,000 (93.5%).
- Net loss of 26,480,451 reduced equity.
- New share issuances of 62,106,000 increased equity.
- Other comprehensive income decreased equity by 2,823,000.
- Other factors decreased equity by 3,604,549.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.48 Million | -43.83% |
| Share Issuances | $62.11 Million | +102.79% |
| Other Comprehensive Income | $-2.82 Million | -4.67% |
| Other Changes | $-3.60 Million | -5.97% |
| Total Change | $- | 93.51% |
Book Value vs Market Value Analysis
This analysis compares Profound Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.93x to 2.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $6.31 | $5.85 | x |
| 2015-12-31 | $4.25 | $5.85 | x |
| 2016-12-31 | $2.66 | $5.85 | x |
| 2017-12-31 | $1.83 | $5.85 | x |
| 2018-12-31 | $1.95 | $5.85 | x |
| 2019-12-31 | $1.29 | $5.85 | x |
| 2020-12-31 | $5.63 | $5.85 | x |
| 2021-12-31 | $3.93 | $5.85 | x |
| 2022-12-31 | $2.50 | $5.85 | x |
| 2023-12-31 | $1.47 | $5.85 | x |
| 2024-12-31 | $2.44 | $5.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Profound Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -260.45%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.16x
- Recent ROE (-43.83%) is above the historical average (-126.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -599.66% | 0.00% | 0.00x | 1.08x | $-8.34 Million |
| 2015 | -117.28% | 0.00% | 0.00x | 1.52x | $-12.81 Million |
| 2016 | -110.05% | 0.00% | 0.00x | 1.60x | $-13.25 Million |
| 2017 | -133.10% | -383.77% | 0.18x | 1.97x | $-16.09 Million |
| 2018 | -77.98% | -797.88% | 0.06x | 1.75x | $-17.20 Million |
| 2019 | -106.53% | -364.69% | 0.14x | 2.09x | $-16.65 Million |
| 2020 | -22.21% | -296.03% | 0.07x | 1.07x | $-31.36 Million |
| 2021 | -38.13% | -446.66% | 0.08x | 1.08x | $-38.75 Million |
| 2022 | -55.13% | -429.11% | 0.10x | 1.24x | $-33.87 Million |
| 2023 | -91.50% | -396.85% | 0.16x | 1.41x | $-31.69 Million |
| 2024 | -43.83% | -260.45% | 0.14x | 1.16x | $-32.52 Million |
Industry Comparison
This section compares Profound Medical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Profound Medical Corp (PROF) | $32.14 Million | -599.66% | 0.32x | $169.46 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |